Biomedical Engineering Reference
In-Depth Information
45. Li P, Zhang GY, Zhu P, Wu BQ, Niu Q, Xie Y (2007) Peripheral blood stem cell mobilization
with low dose rhG-CSF in 56 unrelated healthy donors. Zhongguo Shi Yan Xue Ye Xue Za Zhi
15(2):348-351 [Article in Chinese]
46. D'Souza A, Jaiyesimi I, Trainor L, Venuturumili P (2008) Granulocyte colony-stimulating fac-
tor administration: adverse events. Transfus Med Rev 22(4):280-290
47. Petakov M, Balint B, Bugarski D, Jovcic G, Stojanovic N, Vojvodic D et al (2000) Donor
leukocyte infusion—the effect of mutual reactivity of donor's and recipietnt's peripheral blood
mononuclear cell on hematopoietic progenitor cells growth. Vojnosanit Pregl 57(5
Suppl):89-93
48. Wingard JR, Gastineau DA, Leather HL et al (2009) Hematopoietic stem cell transplantation.
A handbook for clinicians. AABB, Bethesda
49. Link H, Schmitz N, Gratwohl A, Goldman JM (1995) Standards for specialist units undertak-
ing blood and marrow stem cell transplants—recommendations from the EBMT. Bone Marrow
Transplant 16:733-763
50. Falini B, Nicoletti I, Martelli MF, Mecucci C (2007) Acute myeloid leukemia carrying cyto-
plasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood
109(3):874-885
51. Breems DA, Löwenberg B (2007) Acute myeloid leukemia and the position of autologous
stem cell transplantation. Semin Hematol 44:259-266
52. Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A et al (2000) Effect of
centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute
Leukaemia Working Party of the European Group for blood and marrow transplantation.
Lancet 355:1393-1398
53. Gökbuget N, Hoelzer D (2008) HSCT for acute lymphoblastic leukemia in adults. In: Apperly
J, Carreras E, Gluckman E, Gratwohl A, Maszi T (eds) Haematopoietic stem cell transplanta-
tion. The EBMT handbook, 5th edn. ESH, Paris, pp 372-379
54. Chaidos A, Kanfer E, Apperley JF (2007) Risk assessment in haemotopoietic stem cell trans-
plantation: disease and disease stage. Best Pract Res Clin Haematol 20:125-154
55. de Witte T, Sanz G (2008) HSCT for myelodysplasia in adults. In: Apperly J, Carreras E,
Gluckman E, Gratwohl A, Maszi T (eds) Haematopoietic stem cell transplantation. The EBMT
handbook, 5th edn. ESH, Paris, pp 380-387
56. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al (2006) Retrospective
comparison of reduced-intensity conditioning and conventional high-dose conditioning for
allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in
myelodysplastic syndromes. Blood 108:836-846
57. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-
year follow up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med
355:2408-2417
58. Apperley JF (2007) Mechanisms of resistence to imatinib in chronic myeloid leukemia. Lancet
Oncol 8:1116-1128
59. Niederwieser D (2008) HSCT for chronic myeloid leukemia in leukaemia in adults. In: Apperly
J, Carreras E, Gluckman E, Gratwohl A, Maszi T (eds) Haematopoietic stem cell transplanta-
tion. The EBMT handbook, 5th edn. ESH, Paris, pp 388-397
60. Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A et al (2011) Comparative
efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-
adjusted indirect comparison of randomized trials. Curr Med Res Opin 27(6):1263-1271
61. Guglielmi C, Arcese W, Brand R et al (2002) Donor lymphocyte infusion for relapsed chronic
myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100:397-405
62. Weisser M, Tischer J, Schnittger S et al (2006) A comparation of donor lymphocyte infusions
or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after
allogeneic stem cell transplantation. Hematologica 91:663-666
63. Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E (2000)
Complete remission of idiopatic myelofibrosis following donor lymphocyte infusion after fail-
ure of allogeneic transplantation: demonstation of a graft-versus-myelofibrosis effect. Bone
Marrow Transplant 26:697-699
